Literature DB >> 7952073

High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum.

A J Harker1, G L Evans, A E Hawley, D M Morris.   

Abstract

A high-performance liquid chromatographic method for the determination of 2'-deoxy-3'-thiacytidine (3TC), a novel dideoxy-nucleoside analogue, in human serum is described. 3TC was extracted from serum samples using Bond Elut Certify solid-phase extraction cartridges prior to reversed-phase chromatography with UV detection. The method has been shown to be valid over the concentration range 10-5000 ng/ml using a 1-ml sample volume, both before and after heat treatment of the samples at 60 degrees C for 3 h. The method has been automated using a Zymark robot and used in the analysis of serum samples from HIV positive patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952073     DOI: 10.1016/0378-4347(94)80092-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  12 in total

1.  Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

Authors:  A E Heald; P H Hsyu; G J Yuen; P Robinson; P Mydlow; J A Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.

Authors:  Boubacar Nacro; Emmanuelle Zoure; Hervé Hien; Hassane Tamboura; François Rouet; Adama Ouiminga; Ali Drabo; Souleymane Yameogo; Alain Hien; Hélène Peyriere; Olivier Mathieu; Deborah Hirt; Jean-Marc Treluyer; Joëlle Nicolas; Vincent Foulongne; Michel Segondy; Philippe van de Perre; Serge Diagbouga; Philippe Msellati
Journal:  Bull World Health Organ       Date:  2011-04-06       Impact factor: 9.408

3.  A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

Authors:  E M Sokal; E A Roberts; G Mieli-Vergani; P McPhillips; M Johnson; J Barber; N Dallow; E Boxall; D Kelly
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.

Authors:  L H Wang; G E Chittick; J A McDowell
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials.

Authors:  K H Moore; G J Yuen; E K Hussey; G E Pakes; J J Eron; J A Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 6.  Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.

Authors:  C M Perry; D Faulds
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of lamivudine.

Authors:  M A Johnson; K H Moore; G J Yuen; A Bye; G E Pakes
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.

Authors:  B U Mueller; L L Lewis; G J Yuen; M Farley; A Keller; J A Church; J C Goldsmith; D J Venzon; M Rubin; P A Pizzo; F M Balis
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis.

Authors:  M A Johnson; G A Verpooten; M J Daniel; R Plumb; J Moss; D Van Caesbroeck; M E De Broe
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

10.  Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure.

Authors:  Ashwin Asari; Heather Iles-Smith; Ya-Chi Chen; Odin J Naderer; Mark A Johnson; Geoffrey J Yuen; Vicky Otto; John A Dunn; Ram Gokal
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.